Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

HIV Infections Clinical Trial

Official title:

Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00958815
• Other study ID #: 18FDG (completed)
• Secondary ID: DK-020579
• Status: Completed
• Phase: N/A
• First received: August 12, 2009
• Last updated: June 22, 2012
• Start date: March 2009
• Est. completion date: March 2010

Study information

• Verified date: June 2012
• Source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

People with diabetes are at increased risk for atherosclerosis and have high CVD morbidity and mortality rates. Tools for detecting and quantifying atherosclerotic pro/regression in people with diabetes and other CVD risk factors lack sensitivity and specificity for molecular level events that occur during the early stages of atherogenesis. Inflammatory macrophage infiltration in the vessel endothelium is an early, molecular level proatherogenic event. Activated macrophages consume glucose at a high rate. Novel in vivo radiotracer PET/CT techniques have been developed to detect, image and quantify molecular level events like macrophage inflammation and glucose utilization (18FDG) in human vessels. We propose to develop and test this novel technique in the Center for Clinical Imaging Research (CCIR) at WUMS. We propose that HIV-infected people with significant CVD risk profiles are a suitable, unique human model for testing these novel imaging techniques. HIV-infected people taking anti-HIV medications develop insulin resistance, T2DM, dyslipidemia, central adiposity, and hypertension. HIV replicates in macrophages and represents a chronic proinflammatory condition. Recent data indicate that HIV+ CVD risk have greater risk for atherosclerosis and MI than HIV-negative people. To test feasibility, we hypothesize that: a.18FDG-PET/CT imaging will detect more macrophage glucose uptake and inflammation in the carotid and aorta arteries of HIV-infected people with CVD risk than in HIV-negative controls; b. radiotracer PET/CT measures of proatherogenic processes will correlate with carotid intima media thickness; a standard measure of carotid atherosclerotic burden. We propose to obtain pilot data that shows feasibility for a novel analytical approach that will expand capabilities for researchers interested in studying the links between diabetes, inflammation, and CVD in humans.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 35 Years to 60 Years

Eligibility

Inclusion Criteria for HIV+ group:

• confirmed HIV+ status

• 35-60 years old

• stable ART for at least the past 4 mos

• CD4 count >200 cells/µL

• HIV RNA <40copies/mL

• fasting glucose=100-126 mg/dL

• 2hr-oGTT glucose=140-200mg/dL

• fasting triglycerides >150mg/dL

• HDL-cholesterol <40mg/dL (men), <50mg/dL (women)

• resting blood pressure>130/85mmHg

• waist circumference >102cm(men), >88cm(women)

• BMI 25-35 kg/m2

For HIV-negative control group:

• Confirmed HIV negative status

• 35-60 years old

• fasting glucose<100mg/dL,

• 2hr-oGTT glucose<140mg/dL

• fasting triglycerides<150mg/dL

• HDL-cholesterol >40mg/dL (men), >50mg/dL(women)

• normal BP (<130/85mmHg)

• no central adiposity (waist circ.<102cm(men), <88cm(women)

• BMI (25-35 kg/m2)

Exclusion Criteria for both groups:

• history of heart disease, MI, stroke, transient ischemic attack, kidney or liver disease (active hepatitis B or C), dementia

• statins, fibrates, TZDs, antihypertensives, low dose aspirin, or other prescribed/over-the-counter agents with anti-inflammatory properties

• cocaine and methamphetamine users

• serum creatinine >1.5 mg/dL

• pregnant women

• cognitive impairment that limits ability to provide voluntary informed consent

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Atherosclerosis
• Cardiovascular Disease
• Cardiovascular Diseases
• HIV Infections
• HIV/AIDS
• Insulin Resistance
• Plaque, Atherosclerotic

Locations

Country	Name	City	State
United States	Washington University School of Medicine	St.Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Yarasheski KE, Laciny E, Overton ET, Reeds DN, Harrod M, Baldwin S, Dávila-Román VG. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm (Lond). 2012 Jun 2 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standard uptake values (SUV) for 18Fluoro-deoxyglucose in the carotid vessels and aorta of HIV-infected people with cardiovascular disease risk factors and compared to the same in HIV-seronegative people with no cardiovascular disease risk factors.		Baseline	No
Secondary	Carotid intima media thickness measures will be compared to carotid 18FDG SUV.		Baseline	No

External Links

•   PIs web page
•   Publication